NASDAQ: HKPDCellyan Biotechnology Co Ltd Stock
$0.62+0.01 (+1.64%)
Updated Mar 16, 2026
HKPD Price
$0.62
Fair Value Price
$0.54
Market Cap
$6.80M
52 Week Low
$0.60
52 Week High
$2.76
P/E
-206x
P/B
1.36x
P/S
0.54x
PEG
N/A
Dividend Yield
N/A
Revenue
$20.31M
Earnings
-$27.06k
Gross Margin
11.9%
Operating Margin
0.66%
Profit Margin
-0.1%
Debt to Equity
0.89
Operating Cash Flow
$569k
Beta
1.32
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
HKPD Overview
Cellyan Biotechnology Co., Ltd, an investment holding company, engages in the over the counter (OTC) pharmaceutical business in Hong Kong and Mainland China. The company provides OTC pharmaceutical cross-border procurement and distribution and e-commerce supply chain services. It also offers custom clearance, drugs enlisting, warehouse, and other logistics services. The company serves e-commerce platform logistics partners, merchants, and pharmaceutical distributors. The company was formerly known as Hong Kong Pharma Digital Technology Holdings Limited and changed its name to Cellyan Biotechnology Co., Ltd in December 2025. Cellyan Biotechnology Co., Ltd was incorporated in 2023 and is based in Yau Tong, Hong Kong.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine HKPD's potential to beat the market
- HKPD doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical Retailer
Industry Rating
F
HKPD
RankedUnranked of 2
RankedUnranked of 2
Be the first to know about important HKPD news, forecast changes, insider trades & much more!
HKPD News
Overview
Due Diligence Score
–
Industry Average (18)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how HKPD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HKPD ($0.62) is overvalued by 14.87% relative to our estimate of its Fair Value price of $0.54 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
HKPD ($0.62) is not significantly undervalued (14.87%) relative to our estimate of its Fair Value price of $0.54 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
HKPD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more HKPD due diligence checks available for Premium users.
Valuation
HKPD fair value
Fair Value of HKPD stock based on Discounted Cash Flow (DCF)
Price
$0.62
Fair Value
$0.54
Overvalued by
15.24%
HKPD ($0.62) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
HKPD ($0.62) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
HKPD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
HKPD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-206x
Industry
-6.16x
Market
32.08x
HKPD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.36x
Industry
-2.1x
HKPD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
HKPD's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
HKPD's Earnings (EBIT) of $133.78k... subscribe to Premium to read more.
Interest Coverage Financials
HKPD's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$9.4M
Liabilities
$4.4M
Debt to equity
0.89
HKPD's short-term assets ($8.73M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HKPD's short-term assets ($8.73M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HKPD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
HKPD's operating cash flow ($569.21k)... subscribe to Premium to read more.
Debt Coverage Financials
HKPD vs Pharmaceutical Retailer Stocks
Cellyan Biotechnology Co Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.